Observational studyThe oncologist2025

PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network.

Nicolas Rippstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.